Inhaled budesonide for early treatment of COVID-19.

Choi, Jae Chol; Kim, Won-Young
The Lancet. Respiratory medicine
2021May ; 98 ( 3 ) :.
PMID : 33991507
ÀúÀÚ »ó¼¼Á¤º¸
Choi, Jae Chol - Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Dongjak-gu, Seoul 06973, South Korea.
Kim, Won-Young - Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Dongjak-gu, Seoul 06973, South Korea. Electronic address: wykim81@cau.ac.kr.
ABSTRACT
keyword
na
MESH
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This correspondce to the Article by Sanjay Ramakrishnan and colleagues1 in The Lancet Respiratory Medicine on the efficacy of inhaled budesonide in the treatment of early COVID-19 illness in people in the community, addressed several issues regarding primary outcomes, viral load, and asthma prevalence;No difference in the decrease in viral load was observed between the budesonide and usual care groups. This finding does not support the additive inhibitory effect of budesonide against SARS-CoV-2.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1016/S2213-2600(21)00217-4
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå